Immunochemotherapy mediated by thermosponge nanoparticles for synergistic anti-tumor effects

Zhao, Yongdan; Song, Qingle; Yin, Yijia; Wang, Tingting; Hu, Xiaomeng; Gao, Xueqin; Gao, Li; Tan, Songwei; Zhang, Zhiping

doi:10.1016/j.jconrel.2017.11.037

Cited by 51 publications

(40 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to CpG oligonucleotides, interleukin-2 (IL-2) is an immune adjuvant used for activating CTLs and natural killer (NK) cells [ 50 ]. Thermosponge nanoparticles (TSNs) composed of mPEG-PLGA loaded with paclitaxel (PTX) in the core and IL-2 in the shell (PTX/IL-2-TSNs) reduced tumor growth and metastasis in a murine melanoma model to a greater extent than did either TSNs loaded with PTX or IL-2, demonstrating the benefit of combining chemotherapy with an immune adjuvant [ 51 ].…”

Section: Therapeutic Modalities That Induce Icdmentioning

confidence: 99%

Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy

et al. 2020

View full text Add to dashboard Cite

Current cancer immunotherapy has limited response rates in a large variety of solid tumors partly due to the low immunogenicity of the tumor cells and the immunosuppressive tumor microenvironment (ITM). A number of clinical cancer treatment modalities, including radiotherapy, chemotherapy, photothermal and photodynamic therapy, have been shown to elicit immunogenicity by inducing immunogenic cell death (ICD). However, ICD-based immunotherapy is restricted by the ITM limiting its efficacy in eliciting a long-term antitumor immune response, and by severe systemic toxicity. To address these challenges, nanomedicine-based drug delivery strategies have been exploited for improving cancer immunotherapy by boosting ICD of the tumor cells. Nanosized drug delivery systems are promising for increasing drug accumulation at the tumor site and codelivering ICD inducers and immune inhibitors to simultaneously elicit the immune response and relieve the ITM. This review highlights the recent advances in nanomedicine-based immunotherapy utilizing ICD-based approaches. A perspective on the clinical translation of nanomedicine-based cancer immunotherapy is also provided.

show abstract

Section: Therapeutic Modalities That Induce Icdmentioning

confidence: 99%

Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Here, the copolymer ratio of poly( d,l ‐lactic acid) (PDLLA) and mPEG‐ Dlink m ‐PDLLA was fixed as 1:1 according to our previous research. [ 15 ] The introduction of F127 in the nanoparticle fabrication was to take advantage of the thermo‐sensitive property to form a core–shell structure with thermo‐sponge property for co‐loading protein. To obtain the stable and small particles for drugs co‐encapsulation, the composition ratio of copolymers (PDLLA and mPEG‐ Dlink m ‐PDLLA) and F127 was optimized according to the ratios of 1:0 (namely, NP pH ), 1:5, 1:10, 1:15, and 1:20 (namely, TSNP pH ).…”

Section: Resultsmentioning

confidence: 99%

“…Based on the previous work, the pH and thermo‐sensitive polymeric nanoparticles loaded with PTX and IL‐12 were prepared by nanoprecipitation. [ 15 ] First, 30 mg of PDLLA 10k , 30 mg of mPEG 5k ‐ Dlink m ‐PDLLA 45k , and 2 mg of PTX were dissolved in 6 mL of acetonitrile. After the materials were completely dissolved, a certain amount of F127 was added (mPEG‐ Dlink m ‐PDLLA/PDLLA and F127 at mass ratio of 1:5, 1:10, 1:15, or 1:20).…”

Section: Methodsmentioning

confidence: 99%

Co‐Delivery of Paclitaxel and Interleukin‐12 Regulating Tumor Microenvironment for Cancer Immunochemotherapy

Shang

Wang

et al. 2020

Adv Healthcare Materials

Self Cite

View full text Add to dashboard Cite

In the treatment of malignant tumors, the combination of chemotherapy that can directly kill tumor cells and immunotherapy that can activate the body's immune system and regulate tumor microenvironments is becoming one of the most promising cancer treatments. However, to co-deliver agents with different physicochemical properties for immunochemotherapy is still facing a challenge. Here, nanoparticles are developed for the co-delivery of the hydrophobic chemotherapeutic drug paclitaxel (PTX) and biomacromolecule interleukin-12 (IL-12) through the acid-sensitive material mPEG-Dlink m -PDLLA and low-temperature expansion effect of Pluronic F127. The nanoparticles encrich in the tumor site, significantly inhibit the growth and metastasis of breast cancer cells 4T1, and prolong the overall survival of tumor-bearing mice. The underlying immune mechanism is further explored. The combination of PTX and IL-12 activates T lymphocytes and NK cells to release IFN-, selectively inhibits regulatory T cells and induces M1-type differentiation of tumor-related macrophages, thereby improving tumorimmunosuppressive microenvironments. This study may provide an effective strategy for cancer immunochemotherapy through co-delivery of chemotherapeutic drug and immune cytokine by the facile thermo-sponge nanoparticles.

show abstract

“…When combined with anti‐PD‐1 and anti‐CTLA‐4, the nanodisc vaccine led to complete tumor regression in ≈88% of mice bearing MC‐38 tumors and ≈90% of mice bearing B16F10 tumors, compared to only ≈25% and ≈38% of mice having complete tumor regression after treatment with free CpG plus peptide neoantigen . The same group also reported delivering immunogenic chemotherapeutics using the same type of nanodisc. In this scenario, doxorubicin‐loaded nanodiscs potentiated a cytotoxic T‐cell response and increased the therapeutic effect of anti‐PD‐1 checkpoint blockade therapy .…”

Section: Nanotechnology For Cancer Vaccine Developmentmentioning

confidence: 96%

Emerging Nano‐/Microapproaches for Cancer Immunotherapy

et al. 2019

View full text Add to dashboard Cite

Cancer immunotherapy has achieved remarkable clinical efficacy through recent advances such as chimeric antigen receptor‐T cell (CAR‐T) therapy, immune checkpoint blockade (ICB) therapy, and neoantigen vaccines. However, application of immunotherapy in a clinical setting has been limited by low durable response rates and immune‐related adverse events. The rapid development of nano‐/microtechnologies in the past decade provides potential strategies to improve cancer immunotherapy. Advances of nano‐/microparticles such as virus‐like size, high surface to volume ratio, and modifiable surfaces for precise targeting of specific cell types can be exploited in the design of cancer vaccines and delivery of immunomodulators. Here, the emerging nano‐/microapproaches in the field of cancer vaccines, immune checkpoint blockade, and adoptive or indirect immunotherapies are summarized. How nano‐/microparticles improve the efficacy of these therapies, relevant immunological mechanisms, and how nano‐/microparticle methods are able to accelerate the clinical translation of cancer immunotherapy are explored.

show abstract

Immunochemotherapy mediated by thermosponge nanoparticles for synergistic anti-tumor effects

Cited by 51 publications

References 67 publications

Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy

Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy

Co‐Delivery of Paclitaxel and Interleukin‐12 Regulating Tumor Microenvironment for Cancer Immunochemotherapy

Emerging Nano‐/Microapproaches for Cancer Immunotherapy

Contact Info

Product

Resources

About